Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells
Related Experiment Video
Updated: Aug 8, 2026

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins
Published on: December 27, 2016
M Medina1, M García-Rocha, R Padilla
1Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Universidad Autónoma de Madrid, Spain. mmedina@mvax.cbm.uam.es
Abstract:
Human tau phosphorylation has been studied in transfected COS-1 cells. Treatment with okadaic acid alters the electrophoretic mobility of human tau protein transiently expressed in transfected cells, due to an increase in the level of phosphorylation. Treatment with okadaic acid also results in an increased phosphorylation of Alzheimer's disease-type phosphoepitopes. Tau phosphorylation within COS-1 cells is partially inhibited by in vivo treatment with DRB, a protein kinase inhibitor. Double treatment of transfected cells with okadaic acid and DRB reveals that phosphorylation of tau protein at the AT8 epitope is achieved by a DRB-resistant protein kinase which is different from that responsible for tau phosphorylation at the SMI-31 epitope, which appears to be sensitive to DRB.
Insights
Okadaic acid increases human tau phosphorylation in transfected cells, affecting Alzheimer's disease-like epitopes. Different protein kinases, one DRB-resistant, mediate tau phosphorylation at AT8 and SMI-31 epitopes.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Human tau protein is crucial in neuronal function.
- Abnormal tau phosphorylation is linked to neurodegenerative diseases like Alzheimer's disease.
- Understanding tau phosphorylation mechanisms is vital for therapeutic development.
Purpose of the Study:
- To investigate the effects of okadaic acid and DRB on human tau phosphorylation in transfected COS-1 cells.
- To differentiate the protein kinases responsible for tau phosphorylation at specific epitopes.
Main Methods:
- Transient expression of human tau protein in COS-1 cells.
- Treatment with okadaic acid (a phosphatase inhibitor) and DRB (a protein kinase inhibitor).
- Analysis of electrophoretic mobility and phosphorylation levels of tau protein, including Alzheimer's disease-type phosphoepitopes (AT8 and SMI-31).
Main Results:
- Okadaic acid treatment increased tau phosphorylation and altered its electrophoretic mobility.
- Okadaic acid treatment enhanced phosphorylation at Alzheimer's disease-type epitopes.
- DRB partially inhibited tau phosphorylation, but AT8 epitope phosphorylation was mediated by a DRB-resistant kinase, distinct from the DRB-sensitive kinase affecting the SMI-31 epitope.
Conclusions:
- The study identifies distinct protein kinases involved in tau phosphorylation at different epitopes.
- Findings suggest specific kinases are responsible for tau modifications relevant to Alzheimer's disease pathology.
- This research provides insights into the complex regulation of tau phosphorylation.
More Related Videos
Related Concept Videos
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...

